PGC
NRXPW

Pacific Grove Capital’s NRX Pharmaceuticals Warrant NRXPW Stock Holding History

Pacific Grove Capital’s Portfolio NRXPW Stock Details NRXPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-50,000
Closed -$20K – 80
2017
Q4 		$20K Buy
+50,000
New +$19.1K 0.01% 75

Other funds holding NRXPW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Pacific Grove Capital's NRXPW Position: Q1 2018 in Review

Pacific Grove Capital sold out of NRX Pharmaceuticals Warrant (NRXPW) in Q1 2018, closing a stake of 50,000 shares — an estimated $20K sold.

Pacific Grove Capital first reported a position in NRXPW in Q4 2017 and held it in 1 quarter. The position peaked at $20K in Q4 2017. 13 funds tracked by Wall St. Rank hold NRXPW as of Q1 2018.

  • Pacific Grove Capital reported no remaining NRX Pharmaceuticals Warrant position as of Q1 2018 after selling out during the quarter.
  • Pacific Grove Capital sold 50,000 NRX Pharmaceuticals Warrant shares in Q1 2018, an estimated $20K.
  • Pacific Grove Capital first reported a position in NRX Pharmaceuticals Warrant in Q4 2017 and held it in 1 quarter.
  • Pacific Grove Capital's NRX Pharmaceuticals Warrant position peaked at $20K in Q4 2017.
  • 13 funds tracked by Wall St. Rank held NRX Pharmaceuticals Warrant as of Q1 2018.

Based on Pacific Grove Capital's 13F filing for Q1 2018, filed 15 May 2018.